Puretech Health Plc (LON:PRTC) Investors: Jefferies International Reconfirms Buy Rating, Sees GBX 235.00/Share

Share with your friends


Jefferies Co Analyst Rating Change Puretech Health Plc LON:PRTC

Puretech Health Plc (LON:PRTC) Rating Maintained

The financial firm have set target of GBX 235.00 on Puretech Health Plc (LON:PRTC) shares. This is 50.16 % from the current stock price. In an analyst note shared with investors and clients on Thursday, 29 October, Jefferies International reconfirmed their Buy rating on shares of PRTC.

LON:PRTC is at the moment trading 3.50% higher at GBX 155.25 as of 06:47 London time. Puretech Health Plc’s stock is 0% in the last 200 days. It has underperformed the S&P500, which has surged 3.33% in the same time.

LON:PRTC Price Chart & Trend

Puretech Health Plc (LON:PRTC) Investors: Jefferies International Reconfirms Buy Rating, Sees GBX 235.00/Share

Source: RightEdge Systems, Yahoo Split & Dividend Adjusted Data and OctaFinance Trading Models

PRTC Stock Chart

Puretech Health Plc (LON:PRTC) Profile

PureTech Health plc (PureTech) is a science-driven healthcare company. The Company’s portfolio includes 12 operating companies, which targets a diverse range of healthcare markets, including psychiatric and cognitive disorders, obesity and metabolic disorders, autoimmune and inflammatory diseases, oncology and dermatological conditions, such as baldness. PureTech is focused on pursuing programmes capable of bringing commercially viable products to identifiable markets.

Puretech Health Plc (LON:PRTC) traded up 3.50% on 29 October, hitting GBX 155.25. A total of 52,407 shares of the company’s stock traded hands. This is down from average of 403,317 shares. Puretech Health Plc has a 52 week low of GBX 122.00 and a 52 week high of GBX 184.30. The company has a market cap of 366.15 million GBP and a P/E ratio of 0.

Get the latest Puretech Health Plc (LON:PRTC) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

Puretech Health Plc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.